Key result
Idiopathic thromboembolism is linked to an ~7-fold higher cancer risk within one year.
Why the study?
There is clear evidence of an association between idiopathic thromboembolism and the subsequent development of cancer, with particularly high cancer incidence within the first year after thromboembolism.
Does warfarin prevent cancer in patients with idiopathic thromboembolism?
Population
Patients with idiopathic thromboembolism
Design
Editorial
Authors
Loading...
Supports early cancer screening after idiopathic thromboembolism; hypothesis-generating and should not yet change practice.
Does warfarin prevent cancer in patients with idiopathic thromboembolism?
Effect estimate: SIR 6.7
Highlights the strong association between idiopathic thromboembolism and subsequent cancer diagnosis, particularly within the first year.
Zielinski et al. (2000) conducted an editorial in Idiopathic thromboembolism and cancer. Idiopathic thromboembolism was evaluated on Development of cancer (SIR 6.7). Idiopathic thromboembolism is associated with a significantly increased risk of cancer development, with a standardized incidence ratio of 6.7 within the first year after the event.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: